Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 30, 2019 - Issue 4
Submit an article Journal homepage
237
Views
8
CrossRef citations to date
0
Altmetric
Pemphigus

Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months

Kamran BalighiDepartment of Dermatology, Razi Hospital, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran;
,
Maryam DaneshpazhoohDepartment of Dermatology, Razi Hospital, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran; ORCID Iconhttp://orcid.org/0000-0003-1020-8895
ORCID Icon,
Zahra AkbariDepartment of Dermatology, Razi Hospital, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran;
,
Soheil TavakolpourGenomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ORCID Iconhttp://orcid.org/0000-0002-6765-8830
ORCID Icon,
Pourya AzimiScientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
&
Arghavan AzizpourDepartment of Dermatology, Razi Hospital, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-2187-5466
ORCID Icon
Pages 346-349 | Received 01 Jun 2018, Accepted 26 Jul 2018, Published online: 12 Sep 2018

References

  • Harman K, Albert S, Black M. Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003;149:926–937.
  • Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet. 1999;354:667–672.
  • Martin LK, Werth VP, Villaneuva EV, et al. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011;64:903–908.
  • Bystryn J-C, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996;132:203–212.
  • Joly P, Mouquet H, Roujeau J-C, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545–552.
  • Tavakolpour S, Mahmoudi H, Balighi K, et al. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131–138.
  • Balighi K, Daneshpazhooh M, Khezri S, et al. Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. Int J Dermatol. 2013;52:862–867.
  • Kasperkiewicz M, Eming R, Behzad M, et al. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges. 2012;10:727–732.
  • Cianchini G, Lupi F, Masini C, et al. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67:617–622.
  • Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58:1043–1046.
  • Wang H-H, Liu C-W, Li Y-C, et al. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95:928–932.
  • Ran NA, Payne AS. Rituximab therapy in pemphigus and other autoantibody-mediated diseases. F1000Res. 2017;6:83.
  • Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148:1031–1036.
  • Arin MJ, Hunzelmann N. Anti-B-cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus–an update. Eur J Dermatol. 2005;15:224–230.
  • Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheumat. 2003;48:2146–2154.
  • Eming R, Nagel A, Wolff-Franke S, et al. Anti-cd20 (rituximab) treatment of pemphigus vulgaris affects both auto aggressive B and T lymphocytes. Exp Dermatol. 2006;15:204.
  • Schmidt E, Seitz C, Benoit S, et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156:352–356.
  • Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet (London, England). 2017;389:2031–2040.
  • Colliou N, Picard D, Caillot F, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Trans Med. 2013;5:175ra30–175ra30.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.